Experimental Drug Shows Benefits Against Melanoma in Early Study
U.S. News & World Report
SUNDAY, June 2 (HealthDay News) — A new drug called lambrolizumab appears to improve outcomes in patients with advanced melanoma, according to the results of a phase 1 trial. Lambrolizumab is an antibody that works by revealing the cancer to the immune system so it can mount a response and kill the cancer cells with few serious side effects, the researchers said.
read all at
by WORLD DRUG TRACKER
DR ANTHONY CRASTO